pairingsPairing
PD-1 failure → TIL therapy
When checkpoint blockade fails in melanoma, harvesting and expanding the patient's own tumour-reactive T cells still works in a third of patients.
Lifileucel approved after anti-PD-1; TIL retains activity because it supplies tumour-reactive T cells that were quantitatively insufficient rather than absent.
Rationale
Checkpoint failure often reflects too few tumour-reactive T cells; TIL therapy multiplies them a thousand-fold.
Evidence
Accelerated approval; 5-year durability data.
Pages like this
not linked directly; found by shared links- PersonAmod A. Sarnaik
Shares Lifileucel, TIL therapy, Melanoma.
- TrialC-144-01
Shares Lifileucel, TIL therapy, Melanoma.
- PersonShari Pilon-Thomas
Shares TIL therapy, Melanoma.
- PersonPamela S. Ohashi
Shares TIL therapy, Melanoma.
- TrialKEYNOTE-006
Shares Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- IdeaRandomise a cheap antihistamine alongside immunotherapy
Shares Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- CompanyIovance Biotherapeutics
Shares Lifileucel, TIL therapy, Melanoma.
- PersonSteven A. Rosenberg
Shares Lifileucel, TIL therapy, Melanoma.